<p>Omeros（纳斯达克代码：OMER - 获取免费报告）可能将在 2025 年 3 月 3 日星期二市场收盘后公布其 2025 年第四季度的财报。分析师预计该公司本季度每股收益为（$0.57）。个人可以访问公司即将发布的 2025 年第四季度财报页面，以获取关于定于 2026 年 3 月 31 日下午 4:00（东部时间）的电话会议的最新信息。</p>
<h2>Omeros 股价下跌 5.0%</h2>
<ul>
<li>你需要了解的突破性动量股</li>
</ul>
<p>纳斯达克代码：OMER 的股票在星期二开盘价为$11.44。Omeros 的 52 周最低价为$2.95，52 周最高价为$17.65。该公司的 50 日移动平均价格为$12.42，200 日移动平均价格为$8.50。该股票的市值为 8.111 亿美元，市盈率为-5.66，贝塔值为 2.45。</p>
<h2>分析师评级上调与下调</h2>
<p>多家股票研究分析师最近对 OMER 股票发表了看法。HC Wainwright 将 Omeros 的目标价从$20.00 上调至$40.00，并在 1 月 8 日的报告中给予该公司 “买入” 评级。Weiss Ratings 在 1 月 22 日的研究报告中重申了对 Omeros 的 “卖出（d-）” 评级。D. Boral Capital 在 1 月 27 日的研究报告中重申了 “买入” 评级，并将 Omeros 的目标价设定为$36.00。最后，Wall Street Zen 在 1 月 10 日的研究报告中将 Omeros 的评级从 “持有” 下调至 “卖出”。一位股票研究分析师给予该股票 “强烈买入” 评级，两位给予 “买入” 评级，一位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，Omeros 的共识评级为 “适度买入”，平均目标价为$40.33。</p>
<p><strong>阅读我们对 Omeros 的最新分析</strong></p>
<h2>内部人士下注</h2>
<p>在 Omeros 的其他新闻中，首席会计官 David J. Borges 在 1 月 13 日星期二出售了 30,000 股该公司的股票。股票以平均价格$12.31 出售，总交易额为$369,300.00。此次出售在向 SEC 的备案中披露，相关信息可通过此超链接获取。当前 12.90% 的股票由公司内部人士持有。</p>
<h2>机构投资者对 Omeros 的看法</h2>
<p>几家对冲基金最近对该公司的持仓进行了调整。怀俄明州在第四季度以约$25,000 的估值新建了 Omeros 的持仓。凯通国际资产管理有限公司在第四季度以约$33,000 的估值购买了 Omeros 的新持仓。Arax Advisory Partners 在第四季度将其在 Omeros 的持股增加了 56.4%。Arax Advisory Partners 现在拥有 5,255 股该生物制药公司的股票，估值为$90,000，此前在上个季度购买了 1,894 股。Osaic Holdings Inc.在第四季度将其在 Omeros 的持股增加了 34.6%。Osaic Holdings Inc.现在拥有 7,547 股该生物制药公司的股票，估值为$130,000，此前在此期间购买了 1,938 股。最后，Abel Hall LLC 在第四季度以约$176,000 的估值购买了 Omeros 的新股份。机构投资者和对冲基金持有该公司 48.79% 的股票。</p>
<h2>Omeros 公司简介</h2>
<p>（获取免费报告）</p>
<p>Omeros Corporation 是一家临床阶段的生物制药公司，专注于小分子和蛋白质治疗药物的发现、开发和商业化。该公司的研究项目针对炎症、补体介导的疾病和中枢神经系统疾病。Omeros 的产品组合包括内部发现的分子和生物制剂，反映了其推进满足高未满足医疗需求的治疗的承诺。</p>
<p>Omeros 首个获得 FDA 批准的产品 Omidria®（苯肾上腺素和氟比洛芬眼内溶液）用于维持瞳孔大小，防止手术中瞳孔缩小，并减少接受白内障手术患者的术后疼痛。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票</li>
<li>埃隆·马斯克已经让我成为 “富有的人”</li>
<li>埃隆的秘密人工智能合作伙伴？</li>
<li>银价$500？“赤字数学” 认为这是可能的。</li>
<li>解锁：埃隆·马斯克的下一个大 IPO</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T01FUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T01FUg"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Omeros 吗？</h2>
<p>在考虑 Omeros 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄向客户推荐在更广泛的市场注意到之前立即购买……而 Omeros 并不在名单上。</p>
<p>虽然 Omeros 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

标普生物技术 ETF - SPDR

医疗业 ETF - SPDR

标普全球医疗股指数 ETF - iShares

<p>Omeros（纳斯达克代码：OMER）将于 3 月 3 日公布 2025 年第四季度财报，分析师预测每股亏损 0.57 美元。该股目前下跌 5.0%，交易价格为 11.44 美元，市值为 8.111 亿美元。最近的分析师评级中，HC Wainwright 给予 “买入” 评级，目标价为 40.00 美元，而 Weiss Ratings 则维持 “卖出” 评级。机构投资者持有该公司 48.79% 的股份，该公司专注于开发用于治疗炎症和中枢神经系统疾病的疗法。Omeros 首个获得 FDA 批准的产品是用于白内障手术的 Omidria®</p>

<p>Omeros (NASDAQ:OMER - Get Free Report) will likely be announcing its Q4 2025 results after the market closes on Tuesday, March 3rd. Analysts expect the company to announce earnings of ($0.57) per share for the quarter. Individuals may visit the the company's upcoming Q4 2025 earning results page for the latest details on the call scheduled for Tuesday, March 31, 2026 at 4:00 PM ET.</p>
<div class="lb-trans"><p>Omeros（纳斯达克代码：OMER - 获取免费报告）可能将在 2025 年 3 月 3 日星期二市场收盘后公布其 2025 年第四季度的财报。分析师预计该公司本季度每股收益为（$0.57）。个人可以访问公司即将发布的 2025 年第四季度财报页面，以获取关于定于 2026 年 3 月 31 日下午 4:00（东部时间）的电话会议的最新信息。</p>
</div><h2>Omeros Stock Down 5.0%</h2>
<div class="lb-trans"><h2>Omeros 股价下跌 5.0%</h2>
</div><ul>
<li>Breakout Momentum Plays You Need to Know About</li>
</ul>
<div class="lb-trans"><ul>
<li>你需要了解的突破性动量股</li>
</ul>
</div><p>Shares of NASDAQ:OMER opened at $11.44 on Tuesday. Omeros has a fifty-two week low of $2.95 and a fifty-two week high of $17.65. The firm's 50 day moving average price is $12.42 and its 200 day moving average price is $8.50. The stock has a market cap of $811.10 million, a price-to-earnings ratio of -5.66 and a beta of 2.45.</p>
<div class="lb-trans"><p>纳斯达克代码：OMER 的股票在星期二开盘价为$11.44。Omeros 的 52 周最低价为$2.95，52 周最高价为$17.65。该公司的 50 日移动平均价格为$12.42，200 日移动平均价格为$8.50。该股票的市值为 8.111 亿美元，市盈率为-5.66，贝塔值为 2.45。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级上调与下调</h2>
</div><p>A number of equities research analysts have recently weighed in on OMER shares. HC Wainwright raised their price objective on shares of Omeros from $20.00 to $40.00 and gave the company a &#34;buy&#34; rating in a report on Thursday, January 8th. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Omeros in a research report on Thursday, January 22nd. D. Boral Capital reiterated a &#34;buy&#34; rating and set a $36.00 price target on shares of Omeros in a research note on Tuesday, January 27th. Finally, Wall Street Zen downgraded shares of Omeros from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note on Saturday, January 10th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Omeros has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $40.33.</p>
<div class="lb-trans"><p>多家股票研究分析师最近对 OMER 股票发表了看法。HC Wainwright 将 Omeros 的目标价从$20.00 上调至$40.00，并在 1 月 8 日的报告中给予该公司 “买入” 评级。Weiss Ratings 在 1 月 22 日的研究报告中重申了对 Omeros 的 “卖出（d-）” 评级。D. Boral Capital 在 1 月 27 日的研究报告中重申了 “买入” 评级，并将 Omeros 的目标价设定为$36.00。最后，Wall Street Zen 在 1 月 10 日的研究报告中将 Omeros 的评级从 “持有” 下调至 “卖出”。一位股票研究分析师给予该股票 “强烈买入” 评级，两位给予 “买入” 评级，一位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，Omeros 的共识评级为 “适度买入”，平均目标价为$40.33。</p>
</div><p><strong>Read Our Latest Analysis on Omeros</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 Omeros 的最新分析</strong></p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other Omeros news, CAO David J. Borges sold 30,000 shares of the firm's stock in a transaction on Tuesday, January 13th. The shares were sold at an average price of $12.31, for a total transaction of $369,300.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 12.90% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在 Omeros 的其他新闻中，首席会计官 David J. Borges 在 1 月 13 日星期二出售了 30,000 股该公司的股票。股票以平均价格$12.31 出售，总交易额为$369,300.00。此次出售在向 SEC 的备案中披露，相关信息可通过此超链接获取。当前 12.90% 的股票由公司内部人士持有。</p>
</div><h2>Institutional Investors Weigh In On Omeros</h2>
<div class="lb-trans"><h2>机构投资者对 Omeros 的看法</h2>
</div><p>Several hedge funds have recently made changes to their positions in the business. State of Wyoming acquired a new position in Omeros in the 4th quarter valued at about $25,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Omeros in the 4th quarter valued at approximately $33,000. Arax Advisory Partners grew its stake in shares of Omeros by 56.4% in the 4th quarter. Arax Advisory Partners now owns 5,255 shares of the biopharmaceutical company's stock valued at $90,000 after purchasing an additional 1,894 shares during the last quarter. Osaic Holdings Inc. increased its holdings in shares of Omeros by 34.6% in the fourth quarter. Osaic Holdings Inc. now owns 7,547 shares of the biopharmaceutical company's stock valued at $130,000 after purchasing an additional 1,938 shares during the period. Finally, Abel Hall LLC purchased a new stake in shares of Omeros during the fourth quarter worth approximately $176,000. Institutional investors and hedge funds own 48.79% of the company's stock.</p>
<div class="lb-trans"><p>几家对冲基金最近对该公司的持仓进行了调整。怀俄明州在第四季度以约$25,000 的估值新建了 Omeros 的持仓。凯通国际资产管理有限公司在第四季度以约$33,000 的估值购买了 Omeros 的新持仓。Arax Advisory Partners 在第四季度将其在 Omeros 的持股增加了 56.4%。Arax Advisory Partners 现在拥有 5,255 股该生物制药公司的股票，估值为$90,000，此前在上个季度购买了 1,894 股。Osaic Holdings Inc.在第四季度将其在 Omeros 的持股增加了 34.6%。Osaic Holdings Inc.现在拥有 7,547 股该生物制药公司的股票，估值为$130,000，此前在此期间购买了 1,938 股。最后，Abel Hall LLC 在第四季度以约$176,000 的估值购买了 Omeros 的新股份。机构投资者和对冲基金持有该公司 48.79% 的股票。</p>
</div><h2>Omeros Company Profile</h2>
<div class="lb-trans"><h2>Omeros 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company's research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros's portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.</p>
<div class="lb-trans"><p>Omeros Corporation 是一家临床阶段的生物制药公司，专注于小分子和蛋白质治疗药物的发现、开发和商业化。该公司的研究项目针对炎症、补体介导的疾病和中枢神经系统疾病。Omeros 的产品组合包括内部发现的分子和生物制剂，反映了其推进满足高未满足医疗需求的治疗的承诺。</p>
</div><p>Omeros's first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.</p>
<div class="lb-trans"><p>Omeros 首个获得 FDA 批准的产品 Omidria®（苯肾上腺素和氟比洛芬眼内溶液）用于维持瞳孔大小，防止手术中瞳孔缩小，并减少接受白内障手术患者的术后疼痛。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Omeros</li>
<li>Elon Musk already made me a “wealthy man”</li>
<li>Elon’s Secret AI Partner?</li>
<li>Silver $500? The &#34;Deficit Math&#34; says it's possible.</li>
<li>Unlocked: Elon Musk’s Next Big IPO</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票</li>
<li>埃隆·马斯克已经让我成为 “富有的人”</li>
<li>埃隆的秘密人工智能合作伙伴？</li>
<li>银价$500？“赤字数学” 认为这是可能的。</li>
<li>解锁：埃隆·马斯克的下一个大 IPO</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T01FUg" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=OMER"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Omeros Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Omeros 吗？</h2>
</div><p>Before you consider Omeros, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Omeros 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omeros wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄向客户推荐在更广泛的市场注意到之前立即购买……而 Omeros 并不在名单上。</p>
</div><p>While Omeros currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Omeros 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

奥麦罗制药（OMER）预计将在周二公布财报